-
Two major U.S. guidelines update: Lung cancer colorectal cancer screening age is advanced to 45 years old!
Time of Update: 2021-03-21
Recently, the United States Preventive Services Task Force (USPSTF) and the American College of Gastroenterology (ACG) have successively released the latest editions of lung and colorectal cancer screening guidelines.
-
Classic reappearance: After T2N0M0 (7th edition) patients receive adjuvant chemotherapy, the 5-year OS rate has a significant benefit
Time of Update: 2021-03-21
In patients receiving adjuvant chemotherapy, the 5-year OS rate ranges from 64% in the S6-7 group to 67% in the S3 group (Figure 1 and Table 1), which means: the size is 3.
-
Japanese AFTERCAB study: Enzalutamide + ADT vs. Flutamide + ADT
Time of Update: 2021-03-21
Enzalutamide+ADT may become the first-line androgen treatment option for patients with metastatic or non-metastatic CRPC who have progressed in the treatment of bicalutamide+ADT in Japan.
-
[Heavyweight] Zhu Huanzhang’s team reported that chemokine receptor modification CART can improve its anti-tumor activity in vivo
Time of Update: 2021-03-21
Click on the translational medicine website above to subscribe to our dry goods | Reliable | Practical Recently, the team of Professor Zhu Huanzhang of Fudan University reported that in the NSG mouse
-
Selected reviews in the field of oncology in Trends journals
Time of Update: 2021-03-21
Today, our Trends editors have selected excellent review articles in various fields of oncology for everyone, for the "Precision Oncology: Progress, Challenges and Commitments" academic session organized by Cell Press and Beijing Municipal Science and Technology Commission on 25-26 this month.
-
Professor Xu Jianming: KEYNOTE-181 brings a historic breakthrough for the treatment of esophageal cancer
Time of Update: 2021-03-21
KEYNOTE-181 clinical study of the Chinese subgroup data analysis results show that pembrolizumab in the second-line treatment of PD-L1 positive [comprehensive positive score (CPS) ≥ 10] inoperable locally advanced and metastatic esophageal cancer for 12 months The survival rate reached 53%, which was more than 3 times that of the chemotherapy group (16.
-
2021 EBMT | CAR.CD123-NK cells are expected to bring new treatment strategies for CD123-positive children with AML
Time of Update: 2021-03-21
The high expression of CD123 in AML leukemia stem cells is a potential new target for CAR cell therapy.
9%) in vitro, and showed significant anti-leukemia activity against CD123-positive tumor cells (Figure A below) ).
-
Prof. Zhixiang Shen: Gerritinib opens a new era of targeted therapy for FLT3 mutant AML
Time of Update: 2021-03-21
On February 4, 2021, Sigatan® (geritinib fumarate tablets) was approved by the National Medical Products Administration (NMPA) for the treatment of FLT3 mutation-positive relapsed or refractory AML, marking China FLT3 mutant AML patients usher in the first targeted therapy drug, opening a new era of targeted therapy.
-
Prevention of liver cancer see authoritative guidelines | 2021 version of primary liver cancer secondary prevention consensus recommendations
Time of Update: 2021-03-21
Recently, the famous Hong Kong movie star Wu Mengda and the well-known mainland musician Zhao Yingjun have passed away from liver cancer, and the world can't help but sigh. Hepatocarcinoma is known
-
Uti Delong was approved for listing in China: new opportunities for advanced breast cancer treatment, recommended by CSCO guidelines!
Time of Update: 2021-03-21
Based on the results of the BG01-1312L study, Utidelon has also been recommended by the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2020 Edition) for the rescue chemotherapy of HER2-negative advanced breast cancer that has failed anthracycline and taxane treatments.
-
FIB-4 score after 1 year of antiviral therapy can predict the risk of liver cancer in patients with non-cirrhosis | Research Express
Time of Update: 2021-03-21
The results of the study found that the level of FIB-4 in these patients 1 year after treatment was related to the occurrence of hepatocellular carcinoma, and was better than the level of FIB-4 before treatment (Figure 1).
-
Gilead's CAR-T therapy won a third adaptation; the Nobel Prize-winning founding company completed the first editing of bone marrow cells in CRISPR
Time of Update: 2021-03-21
Recently, Eli Lilly and Company announced that the latest results of phase 3 clinical trials showed that neutralizing antibodies bamlanivimab (LY-CoV555, 700 mg) and etesevimab The combination therapy (LY-CoV016, 1400 mg) can reduce the risk of hospitalization or death of early high-risk COVID-19 patients by 87%.
-
FGFR4 single-domain antibody development, sword finger malignant rhabdomyosarcoma in children
Time of Update: 2021-03-21
FGF19-FGFR4 signaling pathway (Document 2) FGFR4 single-domain antibody development Single-domain antibody has a small molecular weight and good tissue penetration.
In vitro binding of FGFR4 targeting liposomes to verify the construction of CAR-T by single domain antibodies and its killing effect on rhabdomyosarcoma cells.
-
Eur Radiol: What is the impact and significance of renal mass texture analysis in different stages of kidney CT?
Time of Update: 2021-03-21
consensus Recently, a study published in the journal European Radiology compared the texture analysis of solid renal masses in the plain scan (NECT) phase, cortical medulla (CM) phase, and nephrography (NG) phase in kidney CT scan schemes ( The difference in TA) characteristics and diagnostic performance clarify which phase should be used as the best phase for diagnosis.
-
"Science" has been published three times in a row: the two "unpredictable" sites for preventing cancer!
Time of Update: 2021-03-21
This is reflected in three different papers published this time: In the main issue of Science, the research team tested the therapeutic effect of H2-scDb in mice with multiple myeloma models (with the TP53-R175H mutation) .
-
Libtayo improves the survival rate of cervical cancer patients!
Time of Update: 2021-03-21
According to the recommendation of the Independent Data Monitoring Committee (IDMC), the phase III clinical trial of Libtayo (cemiplimab) for the treatment of patients with recurrent/metastatic cervical cancer who had previously received chemotherapy will be discontinued early.
-
Eur Radiol: MR texture analysis to identify the malignant possibility of pancreatic ductal papillary mucinous tumors!
Time of Update: 2021-03-21
Recently, a study published in the journal European Radiology explored the application value of MR performance and texture analysis in predicting the malignant potential of intrapancreatic papillary mucinous tumors (IPMN), providing a noninvasive imaging method for clinical assessment of the malignant potential of IPMN means.
-
Express | KRAS inhibitors add new force, Eli Lilly's innovative therapy is about to start clinical trials
Time of Update: 2021-03-21
A few days ago, Eli Lilly and Company announced that it will announce the preclinical research results of its next-generation KRAS G12C specific inhibitor LY3537982 at the AACR annual meeting in April this year.
Retrieved March 11, 2021 from https:// at-amgen-and-mirati-plans-2021-clinical-trial[2] 1259-Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor.
-
PD-1 antibody "new partner": fusion of IL-21 has greatly improved anti-tumor efficacy
Time of Update: 2021-03-21
html">TumorIn a study published in Nature Communications, researchers from the Institute of Biophysics, Chinese Academy of Sciences developed a PD-1 antibody and IL-21 fusion protein (PD-1AB21), which can block PD- 1 Targeting IL-21 to PD-1 expressing T cells while interacting with PD-L1.
-
J Thorac Oncol: Comparison of the efficacy of RovalPituzumab tesiine and topotecan as second-line treatment options for small cell lung cancer
Time of Update: 2021-03-20
TAHOE is an open-label randomized phase 3 study designed to compare the efficacy and safety of Rova-T and topotecan as a second-line treatment for advanced or metastatic small cell lung cancer with high DLL3 expression.
